Host factors in chronicity of hepatitis B virus infection and their significances in clinic

World Chinese Journal of Digestology

Volumn 9, Issue 1, 2001, Pages 66-69

  Shi, H ^a   Wang, F S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HOST RESISTANCE; REVIEW; VIRUS INFECTION;

EID: 0035137021     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. WHO spearheads global initiative to eradicate hepatitis B
2. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16-year populationbased study
3. Estimates of the worldwide mortality from 25 cancers in 1990
4. Viral dynamics in hepatitis B virus infection
5. Fulminant hepatitis associated with hepatitis B virus e antigen-negative infection: Importance of host factors
6. Sex differences in response to hepatitis B infection among patients receiving chronic dialysis treatment
7. Age, gender and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area of hepatitis B virus infection
8. Epidemiology of liver cancer in Europe
9. Factors predictive of liver cirrhosis in patients with chronic hepatitis B: A multivariate analysis in a longitudinal study
10. The incidence of hepatocellular carcinoma in New Zealand
11. Problems in the management of chronic hepatitis B with interferon: Experience in a randomized multicentre study
12. Genetic and sex-linked factors influencing HBs antigen clearance. I. Nonimmune clearance in inbred strains of mice
13. Neonatal hepatitis B infection: Clinical and immunologic considerations
14. Screening for hepatitis B virus markers is not justified in West African transfusion centres
15. Association between an MHC class II allele and clearance of hepatitis B virus in The Gambia
16. Morbidity and mortality from chronic hepatitis B virus infection in family members of patients with malignant and nonmalignant hepatitis B virus-related chronic liver disease
17. Markedly high seroprevalence of hepatitis B virus infection in comparison to hepatitis C vires and human T lymphotropic virus type-1 infections in selected Solomon Islands populations
18. Hepatitis B virus carrier prevalence in New Zealand: Population estimates using the 1987 police and customs personnel survey
19. Epidemiological study of viral hepatitis types A, B, C, D and E among Inuits in West Greenland
20. Ethnicity, socioeconomic status, transfusions and risk of hepatitis B and hepatitis C infection
21. Ethnic differences in the behavior of hepatocellular carcinoma
22. HIV and hepatitis B surveillance in First Nations alcohol and drug treatment centers in British Columbia, Canada
23. Immunization and vaccine-preventable illness, United States, 1992 to 1997
24. Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma
25. Communicable disease in African immigrants in Minneapolis
26. Health of children adopted from China
27. Influence of prior HIV-1 infection on the development of chronic hepatitis B infection
28. Abnormalities of serum amylase and lipase in HIV-positive patients
29. Chronic hepatitis B and C in HIV-infected patients
30. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection
31. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men
32. Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection
33. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial
34. Hepatitis B status of Hmong patients
35. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine
36. Hepatitis B virus markers in Chinese twins
37. Hepatitis B virus and primary hepatocellular carcinoma: Family studies in Korea
38. Anti-HBs response in seroconverting chronic HBV carriers following alpha-interferon treatment
39. HLA class I restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B nucleocapsid antigen
40. Hepatitis B virus immunopathogenesis
41. The role of virus-specific CDS(+) cells in liver damage and viral control during persistent hepatitis B virus infection
42. Association of chronic active hepatitis and HLA B35 in patients with hepatitis B virus
43. Cytotoxic T lymphocyte responses and CTL epitope escape mutation in HBsAg, anti-HBe positive individuals
44. HLA antigens in patients with various courses after hepatitis B virus infection
45. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection
46. HLA-DRB! * 1301 and * 1302 protect against chronic hepatitis B
47. Class II HLA alleles and hepatitis B virus persistence in African Americans
48. HLA and hepatitis B infection
49. Relationship of histocompatibility groups to chronic HBV infections
50. The HLA-I and HLA-II expression evaluation in liver biopsy specimens of patients with chronic viral hepatitis
51. Absence of association between HLA antigen and chronicity of viral hepatitis in haemodialyzed patients
52. Association between hepatitis B virus infection and HLA-DR type in Korea
53. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice
54. The immunogenetics of human infectious diseases
55. Increased production of tumor necrosis factor alpha in chronic hepatitis B virus infection
56. Tumor necrosis factors in patients with chronic hepatitis B virus infection
57. Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection
58. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles
59. A polymorphic variation in a putative regulation box of the TNFA promoter region
60. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection
61. Woodchuck lymphotoxin-alpha, -beta and tumor necrosis factor genes: Structure, characterization and biological activity
62. Induction of apoptosis in mature T cells by tumour necrosis factor
63. Mannan-binding lectin and C1q bind to distinct structures and exert differential effects on macrophages
64. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease
65. Mannose binding protein gene mutations associated with unusual and severe infections in adults
66. Mutation of gene for mannose-binding protein associated with chronic hepatitis B viral infection
67. Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection
68. No association between mannose-binding lectin alleles and susceptibility to chronic hepatitis B virus infection in German patients
69. Mannose binding protein deficiency is not associated with malaria, hepatitis B carriage nor tuberculosis in Africans
70. Vitamins and the regulation of the immune response
71. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene
72. Association of HLA-DR14-DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan
73. Immune response against HBsAg vaccine
74. Survey of coverage, strategy and cost of hepatitis B vaccination in rural and urban areas of China
75. Hepatitis B vaccination in infancy in The Gambia: Protection against carriage at 9 years of age
76. Immunological approaches to the breakdown of hepatitis B viral persistence
77. Update therapy of chronic hepatitis B in China: Recent progress
78. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways
79. Interferon in the management of chronic hepatitis B
80. Effect of alpha-interferon treatment in patients with hepatitis B e antigen - Positive chronic hepatitis B. A meta-analysis
81. The treatment of chronic viral hepatitis
82. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
83. Gene therapy of viral hepatitis and hepatocellular carcinoma
84. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group
85. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
86. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
87. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
88. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
89. Isolation and characterization of human peripheral blood dendritic cells
90. Human and murine dermis contain dendritic calls. Isolation by means of a novel method and phenotypical and functional characterization
91. Virus-induced immune deficiency disease AIDS: Direct pathogenic effect of the virus or immunopathology?
92. Dendritic cell ontogeny: A human dendritic cell lineage of myeloid origin
93. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice
94. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals